Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Alto Neuroscience, Inc.
Alto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology
December 11, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Tickers
ANRO
Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 12, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Tickers
ANRO
Alto Neuroscience to Participate in Upcoming Investor Conferences
November 04, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Tickers
ANRO
Alto Neuroscience Reports Topline Results from a Phase 2b Trial Evaluating ALTO-100 as a Treatment for Major Depressive Disorder
October 22, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Tickers
ANRO
Alto Neuroscience Announces Peer-Reviewed Publication in the Journal of Clinical Psychiatry Demonstrating Baseline Cognitive Performance is Not a Moderator of Response to Standard-of-Care Antidepressants
September 04, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Tickers
ANRO
Alto Neuroscience to Participate in Upcoming Investor Conferences
September 03, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Tickers
ANRO
Alto Neuroscience Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 13, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Tickers
ANRO
Alto Neuroscience Receives Funding Award from Wellcome Trust to Accelerate Development of ALTO-100 in Bipolar Depression Leveraging Precision Psychiatry Approach
July 25, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Tickers
ANRO
Alto Neuroscience Announces Enrollment Completion in Phase 2b Study of ALTO-100 in Major Depressive Disorder
July 16, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Tickers
ANRO
Alto Neuroscience Initiates Phase 2 Study of ALTO-101, a Novel PDE4 Inhibitor, in Cognitive Impairment Associated with Schizophrenia
June 20, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Tickers
ANRO
Amit Etkin, M.D., Ph.D., Founder and CEO of Alto Neuroscience, Named an EY Entrepreneur Of The Year® 2024 Bay Area Award Winner
June 18, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Tickers
ANRO
Alto Neuroscience to Present at the Jefferies Global Healthcare Conference
May 29, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Tickers
ANRO
Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer
May 21, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Tickers
ANRO
Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 14, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Tickers
ANRO
Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific Conferences
May 09, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Tickers
ANRO
Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia
April 23, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Tickers
ANRO
Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder
April 03, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Tickers
ANRO
Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights
March 21, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Tickers
ANRO
Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors
March 11, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Tickers
ANRO
Alto Neuroscience to Participate in Upcoming Investor Conferences
March 07, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Tickers
ANRO
Alto Neuroscience to Present at the TD Cowen 44th Annual Healthcare Conference
February 27, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Tickers
ANRO
Alto Neuroscience Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
February 06, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Tickers
ANRO
Alto Neuroscience Announces Pricing of Upsized Initial Public Offering
February 01, 2024
From
Alto Neuroscience, Inc.
Via
Business Wire
Alto Neuroscience Announces Data from Presentations at the 62nd Annual Meeting of the American College of Neuropsychopharmacology
December 07, 2023
From
Alto Neuroscience, Inc.
Via
Business Wire
Alto Neuroscience Announces Positive Results from Phase 2 Study of ALTO-300 in Major Depressive Disorder
December 04, 2023
From
Alto Neuroscience, Inc.
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.